Stockscreener 앱 받기
0.9234
6.73%
-0.0666
시간 외 거래:
.94
0.0166
+1.80%
전일 마감가:
$0.99
열려 있는:
$0.9779
하루 거래량:
514.66K
Relative Volume:
1.06
시가총액:
$14.33M
수익:
-
순이익/손실:
$-12.16M
주가수익비율:
-0.8673
EPS:
-1.0647
순현금흐름:
$-9.68M
1주 성능:
-13.70%
1개월 성능:
-13.70%
6개월 성능:
-48.70%
1년 성능:
-11.21%
1일 변동 폭
$0.92
$1.00
1주일 범위
$0.92
$1.11
52주 변동 폭
$0.6554
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
명칭
Hoth Therapeutics Inc
전화
(646)756-2997
주소
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.9234 | 15.36M | 0 | -12.16M | -9.68M | -1.0647 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-10-15 | 개시 | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc 주식(HOTH)의 최신 뉴스
Fed Meeting: Will Hoth Therapeutics Inc announce a stock splitMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Aug EndMonth: How much upside does Hoth Therapeutics Inc have2026 Setups & Advanced Technical Signal Analysis - baoquankhu1.vn
Hoth Therapeutics reports preclinical data on obesity treatment - Investing.com Nigeria
Hoth Therapeutics reports preclinical data on obesity treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model - PR Newswire
ETF Watch: Will Hoth Therapeutics Inc. benefit from rising consumer demandWeekly Profit Summary & Stock Portfolio Risk Control - baoquankhu1.vn
Market Outlook: Is Hoth Therapeutics Inc benefiting from innovation trendsPortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Published on: 2026-03-07 13:26:02 - baoquankhu1.vn
Jobs Data: Will Hoth Therapeutics Inc announce a stock splitPortfolio Performance Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Breakout Zone: Whats the fair value of Hoth Therapeutics Inc stockEarnings Recap Report & Capital Protection Trade Alerts - baoquankhu1.vn
Hoth Therapeutics (NASDAQ: HOTH) Is Heating Up – New Site Added - Bitget
Hoth Therapeutics Integrates OpenAI API to Advance HT-KIT Oncology Program for Mast Cell-Derived Cancers - geneonline.com
Analyst Maintains Buy Rating for Hoth Therapeutics (HOTH) | HOTH Stock News - GuruFocus
Hoth Therapeutics Deploys OpenAI API to Support Development of HT-KIT - Contract Pharma
Hoth Therapeutics deploys Openai API to advance development of orphan HT-KIT oncology program - marketscreener.com
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program - PR Newswire
EXCLUSIVE: Hoth Therapeutics Integrates OpenAI API To Support Drug Development For Aggressive Cancers - Benzinga
HOTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HOTH.O| Stock Price & Latest News - Reuters
Aug Selloffs: Is Hoth Therapeutics Inc stock trending bullishPortfolio Risk Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
HOTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Hoth Therapeutics adds clinical site for skin toxicity trial - Investing.com India
Hoth Therapeutics Expands Clinical Trial for Cancer Skin Toxicity Treatment - National Today
Hoth Therapeutics adds clinical site for skin toxicity trial By Investing.com - Investing.com Australia
Hoth Therapeutics accelerates HT-001 trial enrollment with new clinical site as patient demand increases - marketscreener.com
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES - PR Newswire
Performance Recap: Will Lufax Holding Ltd Depositary Receipt benefit from geopolitical trendsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
Aug Reactions: Whats the outlook for Hoth Therapeutics Incs sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Will Hoth Therapeutics Inc. announce a stock splitCPI Data & Technical Pattern Recognition Alerts - mfd.ru
HOTH Should I Buy - Intellectia AI
Is Hoth Therapeutics Inc. stock trending bullishJuly 2025 Spike Watch & Technical Pattern Recognition Alerts - mfd.ru
Hoth Therapeutics receives U.S. notice of allowance for novel exon-skipping therapy targeting allergic diseases - marketscreener.com
Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases - TradingView
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases - PR Newswire
Hoth’s obesity treatment outperforms semaglutide in preclinical study - Investing.com Australia
Why Hoth Therapeutics Inc. stock is a must watch in 2025Trade Volume Summary & Pattern Based Trade Signal System - mfd.ru
Hoth’s obesity treatment outperforms semaglutide in preclinical study By Investing.com - Investing.com Nigeria
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics - Intellectia AI
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Asianet Newsable
Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Stocktwits
Hoth Therapeutics announces groundbreaking positive results: HT-VA GDNF surpasses Semaglutide in weight loss - marketscreener.com
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment - Intellectia AI
Hoth Therapeutics rises as early obesity‑drug data in mice shows promise - TradingView
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model - PR Newswire
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study - Benzinga
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation - Eastern Progress
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets - marketscreener.com
Biotech Hoth rejects crypto rumor, says exposure never topped $350K - Stock Titan
Hoth Therapeutics (HOTH) Price Target Increased by 11.11% to 5.10 - Nasdaq
Aug Final Week: Can KVACW outperform in the next rallyTrade Analysis Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Hoth Therapeutics Inc (HOTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):